title: Feasibility of breast conservation after neoadjuvant taxene based chemotherapy in locally advanced breast cancer: a Prospective Phase I trial.
abstract: BACKGROUND
  Neoadjuvant chemotherapy is the standard care for locally advanced breast cancer. Our study aimed at evaluating the feasibility of breast conversation surgery (BCS) after neoadjuvant chemotherapy.
  
  
  METHODS
  Forty five patients had stage IIB (except those with T2N1 disease) and stage IIIA were selected to 3 cycles taxane-based neoadjuvant chemotherapy. Patient who had tumours ≤5 cm underwent a tentative BCS while patients who had tumour size >5 cm underwent radical surgery. Negative margin is essential for BCS. Adjuvant chemotherapy and 3-D radiotherapy ± hormonal treatment were given to all patients.
  
  
  RESULTS
  Thirty four patients had BCS. Response to chemotherapy was the only statistically significant factor which influences the BCS. Incidence of local recurrence was 5.9% for patients who had BCS at a median follow up 24 months.
  
  
  CONCLUSIONS
  Breast conservation is feasible in selected cases of locally advanced, non metastatic cancer breast. We recommend that patients who have tumour size ≤4 cm after chemotherapy are the best candidates for BCS.
authors.affiliation: Department of Biostatistics and Cancer Epidemiology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt. nabiel@hcp-egypt.com.
authors.forename: Mohamed I
authors.initials: MI
authors.lastname: El-Sayed
authors.forename: Doaa W
authors.initials: DW
authors.lastname: Maximous
authors.forename: Mohamed A
authors.initials: MA
authors.lastname: Aboziada
authors.forename: Mostafa E
authors.initials: ME
authors.lastname: Abdel-Wanis
authors.forename: Nabiel Nh
authors.initials: NN
authors.lastname: Mikhail
references.citation: J Cancer Res Ther. 2007 Apr-Jun;3(2):75-80
references.pmid: 17998727
references.citation: Radiother Oncol. 2000 Oct;57(1):69-77
references.pmid: 11033191
references.citation: J Clin Oncol. 2003 Mar 1;21(5):864-70
references.pmid: 12610186
references.citation: Cancer. 1992 Jun 1;69(11):2849-52
references.pmid: 1571916
references.citation: J Clin Oncol. 1997 Aug;15(8):2873-81
references.pmid: 9256131
references.citation: J Clin Oncol. 1998 Aug;16(8):2672-85
references.pmid: 9704717
references.citation: Indian J Cancer. 2005 Jan-Mar;42(1):30-4
references.pmid: 15805689
references.citation: Cancer. 1994 Jan 15;73(2):362-9
references.pmid: 8293401
references.citation: Ann Surg. 1995 Nov;222(5):612-8
references.pmid: 7487207
references.citation: J Am Coll Surg. 2000 Mar;190(3):350-63
references.pmid: 10703863
references.citation: Cancer J Sci Am. 1998 Mar-Apr;4(2):125-31
references.pmid: 9554929
references.citation: Cancer. 1994 Jul 1;74(1 Suppl):453-65
references.pmid: 8004621
references.citation: Int J Radiat Oncol Biol Phys. 1996 Mar 15;34(5):1019-28
references.pmid: 8600084
references.citation: Clin Drug Investig. 2006;26(12):691-701
references.pmid: 17274676
references.citation: Onkologie. 2005 Jun;28(6-7):339-44
references.pmid: 15933422
references.citation: Ann Surg Oncol. 2002 Apr;9(3):228-34
references.pmid: 11923128
references.citation: Gan To Kagaku Ryoho. 2004 Aug;31(8):1187-92
references.pmid: 15332541
references.citation: Clin Cancer Res. 2004 Oct 1;10(19):6622-8
references.pmid: 15475452